ClinicalTrials.gg
RecruitingNCT07456033MODIFYUpdated Aug 17, 2026

A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

A Phase 3 interventional study of Depemokimab and Placebo in Asthma, sponsored by GlaxoSmithKline. Recruiting at 17 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
456
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing depemokimab in Asthma — 3 open to participants now, 3 under way, 3 of them phase 3. depemokimab · Asthma.

Planned enrollment
3rd of 10
456 · median 273
Started
2026
with 1 other
Phase 3
7 of 10
3 open now
Registered
9th of 10
by date
Lead sponsor
10 of 10
GlaxoSmithKline

Among the 10 studies testing depemokimab in Asthma, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is one of 7 in phase 3, and was the 9th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 10 studies testing depemokimab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About depemokimab

depemokimab: first FDA approval 2025 (EXDENSUR), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing depemokimab in Asthma, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • GSK3511294
  • Depemokimab
  • MODIFY
  • Type 2 asthma
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults and adolescents >=12 years of age, at the time of signing the /assent. For countries where local regulations or the regulatory status of study medication permit enrolment of adults only, participants recruited will be >=18 years of age.
  • Participants must have a documented physician diagnosis of asthma for >=2 years that meets the National Heart, Lung, and Blood Institute, National Institute for Health and Care Excellence or Global Initiative for Asthma guidelines
  • Have previously confirmed history of at least 2 exacerbations over the last 3 years prior to screening, with at least 1 of those exacerbations occurring in the previous year prior to Screening Visit 1.

    • Exacerbation requiring treatment with systemic (CS), for at least 3 days, despite the use of low to medium dose Inhaled corticosteroids (ICS)/ Long-acting beta2-adrenergic receptor agonist (LABA).
  • A well-documented requirement for treatment with low to medium dose ICS/LABA (in the 12 months prior to screening visit. Treatment should be stable for 3 months prior to screening. If participants are taking Maintenance and Reliever Therapy/Single Maintenance and Reliever Therapy regularly, the total daily dose should be incorporated into the assessment of low or medium dose ICS.

    • Study will limit enrolment to a maximum of 40 percent (%) of participants on low dose ICS/LABA.
  • Sex and /Barrier Requirements Male or eligible female Participants:

    • Male Participants: Contraception for male participants with female partners is not required.
    • Female Participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
    • Is a participant of nonchildbearing potential (PONCBP) OR
    • Is a participant of (POCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (\<)1%, from at least 14 days prior to the first dose of study intervention until at least 35 weeks after the last administered dose of study intervention.
    • A POCBP must have a negative highly sensitive serum pregnancy test at Screening Visit 1, Exit Visit 11 or Withdrawn from study visit, and a negative highly sensitive urine pregnancy test within 24 hours before the first dose of study intervention.
    • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
    • The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated in relationship to the first dose of study intervention).
    • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  • Capable of giving signed informed consent/assent as which includes compliance with the requirements Randomization inclusion criteria-
  • Type 2 high disease at risk of asthma exacerbations as defined by either:

    • An elevated peripheral blood eosinophils (EOS) count of >=500 cells/microliter (μL) at screening or >=500 cells/μL in the last 3 months prior to the screening visit.

OR

  • An elevated peripheral blood EOS count of >=300 cells/μL at screening OR >=300 cells/μL in the last 3 months prior to the screening visit AND

    • Fractional exhaled nitric oxide >=35 parts per billion (ppb) at screening. OR
    • Documented current Chronic Rhinosinusitis with Nasal Polyps.

Exclusion criteria

Exclusion Criteria:

  • Participants have had 3 or more exacerbations in the last year prior to Visit 1.
  • Participants on maintenance OCS or high dose ICS/LABA for asthma.
  • Participants with a duration of asthma greater than (>)20 years.
  • Presence of a known pre-existing, lung condition other than asthma. This includes (but is not limited to) current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or a history of lung cancer. Participants with current diagnoses of emphysema or chronic bronchitis ( other than asthma) are excluded.
  • Participants with other conditions that could lead to elevated EOS such as hypereosinophilic syndromes including (but not limited to) Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss Syndrome) or eosinophilic esophagitis.
  • Participants who developed an exacerbation within 4 weeks before screening.
  • Participants with a known, pre-existing parasitic infestation within 6 months prior to screening unless treated and evidenced to have been resolved.
  • A known immunodeficiency (e.g. ), other than that explained by the use of CS taken as therapy for asthma.
  • A current or previous history of cancer in remission for less than 12 months prior to screening.
  • Participants who have known, pre-existing, clinically significant cardiac, endocrine, , metabolic, neurological, psychiatric, renal, gastrointestinal, hepatic, hematologic or any other system abnormalities that are uncontrolled with standard treatment.
  • Participants with current diagnosis of vasculitis.
  • Participants who have received treatment with any approved or biologic monoclonal antibody (mAb).
  • A history (or suspected history) of alcohol misuse or substance abuse within 2 years prior to the first dose of study intervention.
  • Current smokers or former smokers with a smoking history of >=20 pack years (number of pack years = [number of cigarettes per day/20] * number of years smoked) and vapers.
  • Participants with allergy/intolerance to a mAb or biologic or any of the of depemokimab.
  • Participants who are pregnant or breastfeeding.
  • Participants who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations.
  • Evidence of clinically significant abnormality in the hematological, biochemical or urinalysis screen at screening (Visit 0), as judged by the investigator.

Liver safety exclusion criteria:

  • (ALT) >2* (ULN).
  • Total >1.5*ULN; For participants with Gilbert's syndrome: can be included with total bilirubin >1.5*ULN as long as direct bilirubin is less than or equal to (\<=)1.5*ULN.
  • Cirrhosis or current unstable liver or biliary disease as per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.

Cardiac safety exclusion criteria:

  • (ECG) Assessment: corrected by Fridericia's formula (QTcF) >=450 millisecond (msec) or QTcF >=480 msec for participants with Bundle Branch Block in the 12-lead ECG central over-read from Screening Visit, or in the 12-lead ECG machine read at Visit 1.
  • Participants are excluded if an abnormal ECG finding from central over read of the 12 lead ECG conducted at Screening Visit is considered to be clinically significant and would impact the participant's participation during the study, based on the evaluation of the investigator.

Randomization exclusion criteria:

  • ECG Assessment: QTcF >=450 msec or QTcF >=480 msec for participants with Bundle Branch Block in the 12-lead ECG central over-read from Screening Visit, or in the 12 lead ECG machine read at Visit 1.
  • ALT >2*ULN.
  • Total bilirubin >1.5*ULN; For participants with Gilbert's syndrome can be included with total bilirubin >1.5*ULN as long as direct bilirubin is \<=1.5*ULN.
  • Participants with a clinically significant asthma exacerbation in the 7 days prior to randomization should have their randomization visit delayed until the investigator considers the participant's asthma to be stable.
  • Maintenance Asthma Therapy: Any changes in the dose or regimen of baseline ICS and/or additional controller medication (except for treatment of an exacerbation) during the run-in period.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
456 participants (estimated)

Study arms

  • Experimental
    Depemokimab

    Participants will be administered depemokimab along with standard of care (SoC).

    Drug: Depemokimab

  • Placebo comparator
    Placebo

    Participants will be administered placebo along with SoC

    Drug: Placebo

Interventions

  • Depemokimab will be administered

    Also known as: GSK3511294

  • DrugPlacebo

    Placebo will be administered

06

What researchers measure

Primary outcomes

  1. Annualized rate of clinically significant exacerbations

    A clinically significant exacerbation is defined as a worsening of asthma requiring the use of systemic corticosteroids.

    Time frame: Up to Week 156

Secondary outcomes

  1. Proportion of participants with clinical remission at 2 years

    Clinical remission defined as no clinically significant asthma exacerbations during the first 2 years of the treatment period, and no maintenance oral corticosteroids (OCS) for asthma at 2 years, and well controlled asthma based on an Asthma Control Test (ACT) greater than or equal to (\>=) 20 at 2 years, and no deterioration of lung function.

    Time frame: At 2 years

  2. Change from Baseline in Asthma Quality of Life Questionnaire (AQLQ) total overall score at 2 years

    The AQLQ is a 32-item self-administered questionnaire designed to measure the impact of asthma on an individuals daily life over the last 2 weeks across four domains: Symptoms, Activity Limitations, Emotional Function, and Environmental Stimuli. Each item is scored on a 7 point scale (1 = severe impairment; 7 = no impairment). The overall score is the mean of all 32 items and ranges from 1.0 (worst quality of life) to 7.0 (best quality of life). Higher scores indicate better quality of life (QoL), with lower impairment on daily functioning and well-being.

    Time frame: Baseline and at 2 years

  3. Change from Baseline in Asthma Control Questionnaire-5 (ACQ-5) score at 2 years

    The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma symptom control. The questions are designed to be self-completed by the participant. The 5 questions enquire about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath, and wheeze) over the previous week. The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated more limitations and lower score with better asthma control.

    Time frame: Baseline and at 2 years

  4. Change from Baseline in post-Bronchodilator Forced expiratory volume in 1 second (FEV1) at 2 years

    FEV1 is defined as the volume of air that can be forced out in one second after taking a deep breath by a person and will be measured by spirometry testing.

    Time frame: Baseline and at 2 years

  5. Change from Baseline in pre-Bronchodilator FEV1 at 2 years

    FEV1 is defined as the volume of air that can be forced out in one second after taking a deep breath by a person and will be measured by spirometry testing.

    Time frame: Baseline and at 2 years

07

Study locations

17 of 17 sites recruiting
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
    Recruiting
  • GSK Investigational Site
    Newport Beach, California 92663, United States
    Recruiting
  • GSK Investigational Site
    Aurora, Colorado 80012, United States
    Recruiting
  • GSK Investigational Site
    Aventura, Florida 33180, United States
    Recruiting
  • GSK Investigational Site
    Kissimmee, Florida 34746, United States
    Recruiting
  • GSK Investigational Site
    Lake Worth, Florida 33460, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33135, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33144, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33173, United States
    Recruiting
  • GSK Investigational Site
    Shreveport, Louisiana 71105, United States
    Recruiting
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
    Recruiting
  • GSK Investigational Site
    DuBois, Pennsylvania 15801, United States
    Recruiting
  • GSK Investigational Site
    Wyomissing, Pennsylvania 19610, United States
    Recruiting
  • GSK Investigational Site
    Rapid City, South Dakota 57702, United States
    Recruiting
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
    Recruiting
  • GSK Investigational Site
    Burke, Virginia 22015, United States
    Recruiting
  • GSK Investigational Site
    Bradford, BD9 6RJ, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2030, 54 months after the start.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 54 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 6, 2026
StartActual
Mar 13, 2026
Primary completionEst.
Sep 23, 2030
CompletionEst.
Sep 23, 2030
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07456033
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Mar 13, 2026
Primary completion
Sep 23, 2030 (estimated)
Completion
Sep 23, 2030 (estimated)
Last update
Aug 17, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Depemokimab

Start the discussion